RUBY News and Press, Rubius Therapeutics Inc. From 05/12/20

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead ...

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...

Rubius Therapeutics (NASDAQ: RUBY ): Q1 GAAP EPS of -$0.60 misses by $0.04 . More news on: Rubius Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing Facility Strong Cash...

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dose...

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report first quarter 20...

CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present precl...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most i...

Citing the dearth of blood donors as people hunker down amid the COVID-19 outbreak, Baird reiterates is bearish opinion (Underperform/$3) on Rubius Therapeutics ( RUBY +4.2% ) based on headwinds the situation presents for the manufacture of its Red Cell Therapeutic (RTC) products. More n...

IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...